Clinical Trials Browser

Phase 1 × INDUSTRY × VTX-2337 × Clear all

NCT03906526 2023-02-24

A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer

Phase 1 Terminated

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT02124850 2019-10-25

A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab

Phase 1 Terminated

Squamous Cell Carcinoma of Head and Neck

NCT00688415 2019-09-25

Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer

Phase 1 Completed

Lymphoma